Johnson & Johnson earnings fall but beat expectations; sales miss

13 October 2015

US health care giant Johnson & Johnson (NYSE: JNJ) today posted third-quarter 2015 revenue of $17.1 billion, down 7.4% compared with the like 2014 period, which missed the forecasts of six analysts surveyed by Zacks, who expected $17.41 billion.

Sales, about half of which are generated from outside the USA, were hit by the strong US dollar, and excluding foreign exchange fluctuations would have shown a 0.8% increase.

The company reported third-quarter net income of $3.36 billion, or earnings per share of $1.20, with earnings, adjusted for amortization costs and non-recurring costs, at $4.2 billion or $1.49 per share, representing decreases of 9.4% and 7.5%, respectively, compared to the same period in 2014. The results topped the average estimate of 11 analysts surveyed by Zacks Investment Research of $1.44 per share. J&J’s shares dipped as much as 2% in pre-market trading but were barely changed (-0.8% at $95.17) by mid-morning following release of the financial results.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK